** Rare disease-focused biopharmaceutical company Zevra Therapeutics' ZVRA.O shares up ~2.57% at $9.18 premarket

** H.C. Wainwright initiates ZVRA coverage with "buy" rating, says stocks remains undervalued

** Brokerage says the co is now positioned to reward investors as a leading rare disease company with commercial and development expertise

** Sets PT at $26, a ~190.5% upside to stock's last close

** All of eight brokerages rate the stock "buy" or higher; their median PT is $25 - LSEG

** As of last close, stock up ~7.3% YTD

(Reporting by Prakhar Srivastava in Bengaluru)

((Prakhar.srivastava2@thomsonreuters.com))